-- Alphamab Oncology（HKG：9966）は、2025年の決算で1億1390万元の損失を計上した。これは前年の1億6630万元の利益から大幅な赤字転換となる。
このがん治療薬開発企業の株価は、水曜日の午前中の取引で3%以上下落した。
1株当たり損失は0.12元で、前年の0.17元の利益から赤字に転落した。
売上高は2024年の6億4010万元から5億6620万元に減少した。
Related Articles
Japan
WTI, Brent Crude Futures Extend Gains Amid Fresh Trump Warning to Iran
Asia
StarHub Names Consumer Business Chief as Deputy CEO
StarHub (SGX:CC3) named Matt Rhys Williams as deputy chief executive officer, effective May 1, according to a Wednesday filing with the Singapore Exchange.Williams will concurrently continue in his role as chief of the consumer business group, the filing stated.
$SGX:CC3
Sectors
Crude Oil Prices Continue Rising as Strait of Hormuz Remains Blocked, Commerzbank Says
Crude oil prices remain on an upward trajectory as the Strait of Hormuz has not yet been opened despite a halt in hostilities, as the situation has worsened due to the U.S. naval blockade against Iran, Commerzbank said in a Tuesday note.Talks between the U.S. and Iran have also come at a standstill, with a new offer from Iran to open the strait unlikely to be considered acceptable by the U.S., the bank noted. Iran is demanding an end to the blockade and the postponement of talks on the nuclear program.Concerns are also growing about a prolonged supply shortage in the oil market. This is also evident in the widening of time spreads, or the price differences between the various contract maturities along with Brent futures curve, according to Commerzbank.The spread between the nearest-month and the next-month Brent futures contracts is once again just under US$7, while the spread between the nearest-month and the seven-month contract is more than $20. These are the highest price premiums for oil available for immediate delivery in three weeks, the bank said.
$CLX1$LCOX1$USO